Search
EyePoint Pharmaceuticals Inc
EYPTAdd to Watchlist
13.980USD
+0.785+5.95%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.16BMarket Cap
LossP/E TTM
More Details of EyePoint Pharmaceuticals Inc Company
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
EyePoint Pharmaceuticals Inc Info
Ticker SymbolEYPT
Company nameEyePoint Pharmaceuticals Inc
IPO dateJan 27, 2005
CEODuker (Jay S)
Number of employees165
Security typeOrdinary Share
Fiscal year-endJan 27
Address480 Pleasant Street, Suite C400
CityWATERTOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02472
Phone16179265000
Websitehttps://eyepointpharma.com/
Ticker SymbolEYPT
IPO dateJan 27, 2005
CEODuker (Jay S)
Company Executives of EyePoint Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
944.09K
+28.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
164.61K
+28.75%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
75.19K
+48.05%
Mr. Fred Hassan
Mr. Fred Hassan
Non-Executive Independent Director
Non-Executive Independent Director
60.00K
--
Dr. Goeran A. Ando, M.D.
Dr. Goeran A. Ando, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. George Elston
Mr. George Elston
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
944.09K
+28.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
649.85K
-0.52%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
182.86K
+21.87%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
164.61K
+28.75%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
105.01K
+57.14%
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
75.19K
+48.05%
FAQs
Who are the top five shareholders of EyePoint Pharmaceuticals Inc?
The top five shareholders of EyePoint Pharmaceuticals Inc are: Dr. Jay S. Duker, M.D.
How many institutions hold shares of EyePoint Pharmaceuticals Inc (EYPT)?
As of 2026Q1, 381 institutions hold shares of EyePoint Pharmaceuticals Inc, with a combined market value of approximately 88.53M, accounting for 105.59% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2754490.00.
What is the biggest source of revenue for EyePoint Pharmaceuticals Inc?
In 2026Q1, the YUTIQ business generated the highest revenue for EyePoint Pharmaceuticals Inc, amounting to 1.60M and accounting for 5.10% of total revenue.